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Progressive loss of substantia nigra dopamine neurons (SN DA) is a hallmark of aging and of Parkinson’s
disease (PD). Mutations in PARK genes cause familial PD forms. Increased expression of alpha-synuclein
(PARK4) is a disease-triggering event in familial PD and also observed in SN DA neurons in sporadic PD
but related transcriptional changes are unknown. With optimized single-cell quantitative real-time
polymerase chain reaction analysis, we compared messenger RNA and microRNA levels in SN DA neu-
rons from sporadic PD patients and controls. Non-optimally matched donor ages and RNA integrities are
common problems when analyzing human samples. We dissected the inﬂuence of distinct ages and RNA
integrities of our samples by applying a speciﬁcally-optimized, linear-mixed-effects model to quantita-
tive real-time polymerase chain reaction-data. We identiﬁed that elevated alpha-synuclein messenger
RNA levels in SN DA neurons of human PD brains were positively correlated with corresponding elevated
levels of mRNAs for functional compensation of progressive SN DA loss and for enhanced proteasomal
(PARK5/UCHL1) and lysosomal (PARK9/ATPase13A2) function, possibly counteracting alpha-synuclein
toxicity. In contrast, microRNA miR-133b levels, previously implicated in transcriptional dysregulation
in PD, were not altered in SN DA neurons in PD.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Parkinson’s disease (PD) is the second most common neurode-
generative disorder. Since the main risk factor for the disease is age,
the number of PD patients is projected to further increase world-
wide (Hindle, 2010). Current pharmaceutical and neurosurgical
therapies provide only symptomatic treatment with no cure avail-
able (Meissner et al., 2011). Clinical core symptoms of PD are caused
by a selective degeneration of dopamine (DA) midbrain neurons,
particularly within the substantia nigra (SN), resulting in a dopa-
mine deﬁcit in striatal target regions (Shulman et al., 2011). Loss of
DA neurons is usually preceded by a cellular accumulation of alpha-BY-NC-ND license (http://
ysiology, University of Ulm,
9 (0)731 500 36200; fax: þ49
cts of the article.
Published by Elsevier Inc. All righsynuclein-positive protein conglomerates, so-called Lewy bodies
(Spillantini et al., 1997). The cause for PD is still unclear, however
mitochondrial, proteasomal as well as lysosomal dysfunctions are
relevant triggers (Gasser et al., 2011). Depending on the ethnic
population, approximately 10%e30% of familial forms of PD are
caused by mutations in one of the several PARK gene loci (PARK1-
15) (Shulman et al., 2011).
In sporadic PD cases, simple Mendelian inheritance patterns are
not observed. Genome-wide analysis of single-nucleotide poly-
morphisms or copy number variations identiﬁed an increasing
number of disease-associated genes (Gasser et al., 2011; Hardy,
2010; Nalls et al., 2011). However, a PD risk prediction based on
validated single-nucleotide polymorphisms is not yet possible
(Mittag et al., 2012). The major validated genetic factor for sporadic
PD is the SNCA gene (Pihlstrom and Toft, 2011). SNCA codes for the
protein alpha-synuclein andwas the ﬁrst gene (PARK1) identiﬁed to
be mutated in familial forms of PD (Polymeropoulos et al., 1997).
Full functions of the alpha-synuclein tetramer are still not clear,
however, it is involved in vesicular trafﬁcking and dopamine releasets reserved.
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of nonmutated wild-type alpha-synuclein because of SNCA gene
duplications or triplications (PARK4) is sufﬁcient to cause familial
forms of PD (Fuchs et al., 2007). Furthermore, elevated levels of
alpha-synuclein messenger RNA (mRNA) in substantia nigra
dopamine neurons (SN DA) neurons have been observed in sporadic
PD (Grundemann et al., 2008; Shulman et al., 2011; Venda et al.,
2010). These ﬁndings point to a key role of wild-type SNCA gene-
dosage for death of DA neurons in sporadic PD (Devine et al.,
2011b; Eriksen et al., 2005). Thus, identifying transcripts that co-
vary in their expression levels with that of SNCA provide strong
evidence for alpha-synuclein-linked pathways that are operative in
SN DA neurons of sporadic PD patients and contribute to PD pa-
thology. However, cell-speciﬁc alpha-synuclein associated changes
in gene expression that occur speciﬁcally in human SN DA neurons,
the most vulnerable neuronal population in PD, are still unknown.
We performed cell-speciﬁc gene expression analysis of selected
genes for individual human SN DA neurons from sporadic PD brains
and controls. Given the emerging role of microRNAs for orches-
trating correlated transcriptional programs, and the suggestion that
miR-133bhas a prominent role for those programsand in PD (Harraz
et al., 2011; Kim et al., 2007), we developed a RT-qPCR protocol for
parallel quantiﬁcation of both mRNA and microRNA at the level of
individual, ultra violet-laser-microdissected (UV-LMD) neurons
from human postmortem brains. For human samples, optimal
matching is commonly not possible, causing a general problem for
gene expression comparison at the RNA level: differences in co-
factors that have a biological (e.g. different ages) or methodolog-
ical (e.g. different RNA integrities) impact on results, and thus
confound comparative gene expression analysis (e.g. comparison
disease vs. controls). To adjust gene expression data for possible
inﬂuences of distinct ages and RNA integrity numbers (RIN) of hu-
man control and PD brain samples (present in our cohort), we
developed a suited linear mixed 3-effects algorithm (Greenland and
Morgenstern, 2001), that has not been applied to gene expression
data before (Ho-Pun-Cheung, 2009; Popova et al., 2008), to dissect
the inﬂuence of distinct ages and RNA integrities of our samples to
the RT-qPCR results in addition to disease state (PD vs. control).
We show that neuromelanine-positive SN DA neurons from
sporadic PD brains with signiﬁcantly elevated SNCA mRNA levels
exhibit a concerted upregulation of distinct dopamine homeostasis
and PARK genes. The positive correlation ofmRNA levelswith that of
SNCA in SN DA neurons points to an orchestrated allostatic dysre-
gulation at the mRNA level in PD. In contrast, we detected no asso-
ciated change of miR-133b levels in individual SN DA neurons in PD.
2. Methods
2.1. Tissue storage and preparation of midbrain sections for UV-
laser microdissection
Details for all 13 human postmortem horizontal midbrain tissue
blocks (provided by the German BrainNet, Grant-No. GA 28, and
Dietmar R. Thal, University of Ulm, Germany) are given in Table 1.
Murine tissue samples for control experiments derived from male
C57BL/6 J WT mice (PN 19). Murine and human midbrain tissue
cryoconservation, handling, sectioning, ﬁxation, and staining were
performed as previously described (Grundemann et al., 2008, 2011).
2.2. Tissue pH measurements, tissue RNA extraction, and RIN
analysis
pH measurements of human postmortem midbrain tissue sam-
ples were performed with a pH Optica micro system and aMicroTip
ﬁber optic pH sensor (World Precision Instruments, Sarasota, FL,USA) calibrated at 4 C (Harrison et al., 1995; Mexal et al., 2006).
Frozen cryosections (12 mm) of eachmidbrainwere harvested, 10 mL
of 4 C cold molecular biology grade water (Eppendorf) were added
per mg tissue and samples were homogenized using a sterile 1 mL
syringeanda21-gaugeneedle. pHwasmeasuredat4 C. Total RNAof
human postmortem horizontal midbrain tissue cryosections was
extracted using the RNeasy Mini Kit (Qiagen). For RNA quality con-
trol, RNA integrity numbers (RINs) were determined using the Agi-
lent 2100 Bioanalyzer systemwith the Agilent RNA 6000 Nano Chip
Kit. Small RNA fractions andmicroRNApercentagewere determined
using the Agilent Small RNA Kit.
2.3. UV-LMD, reverse transcription, and RT-qPCR
UV-LMD and quantitative real-time PCR were performed essen-
tially as described (Grundemann et al., 2008, 2011). qPCR methods
and data are provided according to the “Minimal Information for
Publication of Quantitative Real-Time PCR Experiments (MIQE)
guidelines” (Pihlstrom and Toft, 2011). For all details, see
Supplementary methods. Brieﬂy, 10 pools of 15 neuromelanine-
positive (NMþ) SN neurons each were harvested from each individ-
ual midbrain via UV-LMD (Leica LMD6000) for each gene expression
proﬁling experiment. For parallel qPCR quantiﬁcation of miR-133b
and mRNA, the miScript Reverse Transcription Kit (Qiagen) was
used. A 1/11 volume of the non-puriﬁed complementary DNA (cDNA)
was used as a template for each real-time qPCR in a ﬁnal volume of
20 mL (TaqMan), using 1QuantiTect Probe PCRMasterMix (Qiagen).
All real-time qPCR assays were labeled with 6-carboxyﬂuorescein
(FAM) as reporter and a nonﬂuorescent quencher (BHQ). Real-time
qPCR assay details, amplicons and assay-speciﬁc standard curve pa-
rameters, threshold for cycle analysis, and slopes and Y-intercept of
respective standard curves: see Supplementary Table S1.
For thermal degradation assay, distinct RINs of the same RNA
sample (mouse midbrain) were generated by incubation of RNA
sample at 70 C for 30 minutes (RIN 7.2), 45 minutes (RIN 6.8), and
72 minutes (RIN 5.9).
Relative expression data of midbrain tissue RT-qPCR data
(Supplementary Table S3) were normalized by the geometric mean
from b-actin, TIF-1A, and ENO2 expression:








q with i˛fß-actin; TIF-1A; ENO2g
2.4. Linear mixed effects modeling and adjustment of expression
data to covariates
To adjust for possible confounding inﬂuence of other variables
(in particular age and RIN) on gene expression differences between
control and PD samples, a hierarchical, multivariate linear mixed
effects model with a multi-trait design was ﬁtted to each of the
5 independent RT-qPCR data sets by applying Asreml-R (version 3.0,
VSN International) in the R environment (version 2.15, The
R-Project for statistical computing). Details of the model, its eval-
uation, and the full algorithm are given in the Supplementary
methods, Figures, and Tables.
Brieﬂy, expression values of distinct analyzed genes, determined
via RT-qPCR assays, were deﬁned as different traits, coupled by an
unstructured covariance matrix and similar inﬂuence of RNA
integrity as measured by RIN values. Random effects for gene
dependent Y-intercepts, incorporated at the brain level, accounted
for the hierarchical design of the study (cell samples, brains, and
control ordisease group), and for inter-individual differences in gene
Table 1
Details of human control and PD brain tissue









CTR-SN 1 Hypertonia, coronary infarction 0 I 62, M 31 5.9 6.2 5.08 28
CTR-SN 2 CMV, diabetes, nephritis kidney
transplant
0 II 72, M 6 6.4 6.6 5.91 26.3
CTR-SN 3 Diabetes, hypertonia, pneumonia, ARDS A I 69, F 14 6.6 6.5 11.02 17
CTR-SN 4 Arteriosclerosis 0 I 75, F 24 5.5 6 13.07 19.7
CTR-SN 5 Liver cancer, hepatorenal syndrome 0 0 63, M 24 6 6.3 8.01 26.5
Mean (SEM)
controls (1-5)
68.2  2.52 19.8  4.39 6.08  0.19 6.32  0.12 8.62  1.51 23.5  2.16
CTR-SN 6a Sepsis, mamma carcinoma, CNS micro
abscesses
0 II 68, F 120 5.7 5.9 7.1 28.6
CTR-SN 7a Cervix carcinoma, arterial hypertonia,
COPD, pulmonary embolism, old frontal
micro infarct
0 I 71, F 72 5.67 6.5 5.62 21.3
CTR-SN 8a Lymphoma-NHL-high malignancy,
Bergmann cell gliosis
0 I 72, M 24 5.65 6.6 8.26 31.6
Mean controls
(1e8)
69  1.6 39.38  13.43 5.93  0.14 6.3  0.1 8  0.98 24.88  1.77
PDs
PD-SN 1 PD, multi system atrophy 0 II 80, M 7 6.4 7.1 3.66 11.3
PD-SN 2 PD, AD1, hypertonia pneumonia B III-IV 80, M 23 5.4 6.8 9.24 15.2
PD-SN 3 PD 0 II 79, F 17 5.8 7.3 3.08 12.1
PD-SN 4 PD, AD, heart attack, lung carcinoma 0 0 79, M 23 6.2 7.5 3.06 12.5
PD-SN 5 PD, ovarian cancer, Morbus Sudeck 0 V 73, F 11 5.5 7.7 5.62 19.8
Mean PDs 78.2 ± 1.3 16.2  3.2 5.86  0.19 7.28 ± 0.16 4.93  1.17 14.18 ± 1.55
Details of all 13 humanmidbrain samples are used in this study. Listed for each brain are: additional known diseases, CERAD (Consortium to Establish a Registry for Alzheimer’s
Disease) stage, Braak stage (concerning ADeAlzheimer’s disease), age of donor in years (a), sex (M: male, F: female), postmortem interval (PMI), pH of brain tissue, RNA
integrity number (RIN), and amount of small RNAs with fraction of miRNA (%).
Mean  SEM values and signiﬁcant differences (p < 0.05, marked in bold) are given for the cohort of control and PD brains.
Key: AD, Alzheimer’s disease; ARDS, acute respiratory distress syndrome; CMV, cytomegalie-virus; CNS, central nervous system; COPD, chronic obstructive lung disease; F,
female; M, male; miRNA, microRNA; NHL, non-Hodgkin-lymphoma; PD, Parkinson’s disease.
a CTR-SN controls are not included in experimental series random 1, 2 and miScript 5; PD-SN sporadic Parkinson’s disease cases.
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covariates, was selected on the basis of model performances, quan-
tiﬁed by the Bayesian Information Criterion (BIC, Supplementary
Fig. 1A) and the biological or experimental relevance of possible
confounds (Fig. 1A). BIC values were computed for single-trait
models (TH gene only) of different complexity with the lme func-
tion of the nlme R-package by maximizing the log-likelihood (ML
method) (Pinheiro et al., 2012).
A possible biological effect of age on expression levels of indi-
vidual genes was represented by ﬁxed effects for each gene. A
possible artiﬁcial effect of RNA quality (RIN value) on RT-qPCR re-
sults was modeled as a single ﬁxed effect, allowed to vary randomly
by each gene. This incorporation of RIN effects into the model was
chosen, since the inﬂuence from RNA quality on RT-qPCR results
should be small for short qPCR amplicons that we used in our study
(Fleige and Pfafﬂ, 2006), and thus gene-dependent differences were
expected to be minimal (Fig. 1BeE and Supplementary Fig. S4). But
they should nevertheless be represented by the model (Ho-Pun-
Cheung, 2009; Popova et al., 2008), as RIN values of our PD brains
were signiﬁcantly higher than that of controls.
In addition, we have evaluated the inﬂuence of the confounders
RIN value and age in isolation, by adjusting data for only one of
these covariates (Supplementary Table S4). Comparison of these
results under consideration of proportional change in variance
(PCV) values allows dissecting which covariate has the strongest
effects on the dependent variable.
2.5. General statistics
Datawere analyzed and presented using R (www.r-project.com),
Excel (Microsoft), Igor Pro (Wavemetrics), InStat and Prism (bothGraphPad). Data values are given as mean  standard error of the
mean if not stated otherwise. Statistical differences for data in
Table 1, Supplementary Table S3, and Fig. 3A were tested with Wil-
coxon rank test. Data in Table 2, Supplementary Table S4, Figs. 2 and
3BeE, and Supplementary Fig. S2 were tested with Student t test
(Welch-Test) after logarithmic transformation. Pairwise partial cor-
relation coefﬁcients in Fig.1Awere computedwith the function pcor
from the ppcor R package. The partial correlation factor is the Pear-
son correlation between 2 variables while controlling for all other
variables. Pearson correlations in Fig. 4 and Table 3 were computed
and tested for being different than zero after logarithmic trans-
formationwith standard functions of R. Correlation coefﬁcients of a
gene-pair for control and PD data were tested for signiﬁcant differ-
ences by applying Steiger Z-test. p-values 0.01 were considered to
be statistically signiﬁcant and indicated byasterisk * (p<0.001 and p
< 0.0001 indicated as ** and ***, respectively).
3. Results
3.1. Characterization of human postmortem brain samples and
evaluation of an RT-qPCR protocol for parallel mRNA and microRNA
quantiﬁcation
Eight controls and 5 PD postmortem brains were included in
this study (Table 1). The RNA integrity (RIN) and donor age of PD
brains were 7.28  0.16 and 78.2  1.3 year, respectively, which is
signiﬁcantly higher compared with the control cohort with 6.3 
0.1 and 69  2 years, respectively (RIN, p ¼ 0.008; age, p ¼ 0.016;
for 8 control and 5 PD brains). The relative amount of microRNA
(miRNA) (% miRNA) was also lower in PD (14.2%  1.6%) than in
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Fig. 1. Characterization of human postmortem brain samples and evaluation of RT-qPCR protocols for quantiﬁcation of mRNA and miRNA. (A) Partial correlations between given
parameters of brains analyzed in this study. Correlations between 2 parameters were controlled by the other 4 parameters in each calculation. Positive (red) or negative (blue)
correlation given by orientation and color of ellipses, strength of correlation given by color intensity, and shape of ellipses, signiﬁcant correlation indicated by asterisks. Note the
strong signiﬁcant correlation between RNA quality (given as RNA integrity number; RIN) and disease state (CTR vs. PD), due to signiﬁcant difference of RIN values between control
(CTR, n ¼ 8) and PD (n ¼ 5) brains (see also Table 1). Other correlations were not signiﬁcant. (BeE) Sensitivity and reproducibility of both used RT-qPCR protocols (B/D: random
primer protocol and C/E: miScript OligodT primer protocol) was independent of integrity-levels of RNA used as templates for cDNA synthesis (RIN range: 9.9e5.7 of mouse cDNA,
covering the RIN-spectrum of the human samples of this study). (B/C) Note that sensitivity of qPCR assay (mLdh-2) is similar for all midbrain cDNA samples, each with 4 different
RIN as templates (p > 0.1 in all comparisons; samples generated by thermal degradation of the same midbrain derived RNA for 0e72 minutes at 70 C). (D/E) Results for RIN 9.9 from
panels B and C (standard curve) were used for calculation of relative expression levels of mLdh-2 at different RIN values (range: 9.9e5.9). Regression lines with conﬁdence bands
show no signiﬁcant dependence of gene expression levels from RIN values at all dilutions. Abbreviations: cDNA, complementary DNA; CTR, control; mRNA, messenger RNA; miRNA,
microRNA; PD, Parkinson’s disease; PMI, postmortem interval; RT-qPCR, quantitative real-time polymerase chain reaction.
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Fig. 2. UV-laser microdissection of individual, neuromelanin-positive substantia nigra dopamine neurons of human postmortem Parkinson’s disease (PD) and control brains.
(AeB) Upper row: overview of a control (A) and PD (B) horizontal midbrain kryo-section, containing the substantia nigra, after UV-laser microdissection (UV-LMD) of 15 in-
dividual, neuromelanin-positive neurons. Note the higher integrity of the PD tissue sections. Scale bars: 250 mm. Inserts: photograph of the reaction tube cap for inspection of
proper collection of all neurons before cell-lysis and reverse-transcription. Scale bars: 500 mm. Lower row: individual substantia nigra dopamine neurons before (left) and after
UV-LMD (right) from (A) control and (B) PD brains. Scale bars: 20 mm. Note that all analyzed neuronal SN pools were qPCR-positive for tyrosine hydroxylase (TH). (C) Using the
miScript RT-qPCR protocol, similar degrees of signiﬁcantly elevated alpha-synuclein (SNCA) mRNA levels were detected in remaining SN DA neurons from PD brains compared
with controls, as with our standard protocol (random 1, adapted from Grundemann et al., 2008 and random 2 for independent reproduction). Bar graphs (mean  SEM) show
normalized SNCA expression levels of 3 individual SN DA sample sets from control brains (random 1, miScript 5: n ¼ 5 brains; random 3: n ¼ 8 brains) and PD brains (n ¼ 5). For
details see Table 2. Abbreviations: mRNA, messenger RNA; qPCR, quantitative polymerase chain reaction; SN DA, substantia nigra dopamine neurons; SEM, standard error of the
mean.
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RIN value, as evident from partial correlation coefﬁcients (pcor,
ppcor; Fig. 1A).
To evaluate and consider how differences in RNA quality affect
results of our RT-qPCR experiments we applied 2 approaches. First,
we designed a thermal degradation experiment to test whether our
UV-LMD RT-qPCR protocols (random and miScript) display similar
RT-qPCR resultswith similar amounts of RNAbutwith different RINs
(Grundemann et al., 2008, 2011) (Fig. 1BeE). We generated cDNA
from an identical RNA source (mouse midbrain) with distinct RINs
generated by thermal degradation, either with our previouslypublished “random” protocol (using random hexamer primer) or
with our newmodiﬁed “miScript” protocol (using a combination of
random and oligo-dT primers after polyadenylation ofmiRNAs). The
RIN values ranged from 9.9 (fully intact RNA) to 5.9 (moderately
degraded), covering the RIN spectrum of the human samples
analyzed in this study (Table 1). To evaluate qPCR performance in
dependence of RIN and cDNA amount, we prepared serial cDNA
dilutionspriorqPCR.Results for lactatedehydrogenase,mLdh-2 (and
for other genes, data not shown) were similar for all samples inde-
pendent from RIN or dilution factor as evident from both, threshold
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Fig. 3. Elevated mRNA levels of dopamine release genes and PARK genes in SNCA-
overexpressing SN DA neurons in sporadic PD patients. (A) Levels of miR-133b and
mRNAs for genes involved in DA neuron development and/or maintenance (NURR1,
PITX3) and dopamine homeostasis (TH, DAT, VMAT2), determined via RT-qPCR at the
level of midbrain tissue. Relative values, normalized to a geometrical mean of b-actin,
F. Schlaudraff et al. / Neurobiology of Aging 35 (2014) 2302e2315 2307expression values, respectively (Fig.1D and E); a prerequisite for RT-
qPCR analysis of samples with signiﬁcantly different RIN.
As evident from Fig.1BeE (mousemidbrain) and Fig. 2C, (human
SN DA neurons), our novel miScript RT-qPCR-approach allows
quantiﬁcation of mRNA independently of its integrity (for moder-
ately degraded, RIN> 5.9) of small amounts of RNA (i.e., single cells),
with a similar high sensitivity and reproducibility as our established
protocol based on random hexamer primers (Grundemann et al.,
2008). Quantiﬁcation of SNCA mRNA for human neuromelanine-
and TH-positive SN DA neurons using either the random hexamer
protocol (experimental series random 1 and random 2) or the miS-
cript approach resulted in similar results for control brains and PD
brains analyzed in this study (Fig. 1F) and detected about 7-fold
higher SNCA mRNA levels in surviving SN DA neurons in PD
compared with controls, as we had previously described (experi-
mental series random 1; Grundemann et al., 2008).
3.2. A linear mixed effects model allows data adjustment for
possible age and RIN effects on differential gene expression data of
PD and control SN DA neurons
To further take into account the possible effects of signiﬁcantly
different RINs and ages on gene expression comparison of SN DA
neurons from PD and control brains, we optimized and applied a
linear mixed effects model on our RT-qPCR data. (Koppelkamm
et al., 2011; Popova et al., 2008). The model is described in detail
in Section 2.
Model performance was assessed for TH expression data,
available for all 5 sets of RT-qPCR data from this study. It was
computed as change of the BIC compared with a model that
considered only brain-dependent differences in Y-intercepts to
account for inter-individual differences (in TH expression only)
(Supplementary Fig. 1A) (Schwarz, 1978). The BIC value weights the
goodness-of-ﬁt against model complexity, with low values indi-
cating better model performance. Based on this evaluation of model
performance and the signiﬁcantly different RIN and age values for
PD and control brains, we decided to apply a 3-effects model,
considering inﬂuence of disease state (CTR/PD), ages, and RINs for
expression values of individual brains.
Our model was well applicable to all 5 UV-LMD RT-qPCR data
sets and most analyzed genes (Supplementary Fig. 1BeF and
Supplementary Table S2). Model results were not reliable for PAR-
KIN and PITX3 data (data not shown), as the algorithm did not
converge well (most likely because of low number of samples that
gave positive RT-qPCR results).
3.3. Elevated mRNA levels of dopamine release genes and PARK
genes but not of miR-133b in SN DA neurons from sporadic PD
patients
After having established an RT-qPCR protocol for parallel miRNA
and mRNA quantiﬁcation, as well as the model for analyzingENO2, and TIF-1A. Note signiﬁcantly lower expression of miR-133b and signiﬁcantly
higher levels of only TH in PD SN tissue compared with controls. (BeC) RT-qPCR
analysis of genes as in (A), but at the cell-speciﬁc level of individual SN DA neurons,
without (B) and after (C) adjustment of data for RIN and age effects. Note that miR-
133b levels are not altered in SN DA neurons from PD compared with controls. (D
and E) mRNA levels of PARK-genes in individual SN DA neurons, without (D) and after
(E) model adjustment of data for RIN and age effects. n.a: model-analysis not possible
due to low numbers of samples with positive RT-qPCR results. Bar graphs represent
normalized expression as mean  SEM. For details, see text. Abbreviations: DAT,
dopamine transporter; mRNA, messenger RNA; PD, Parkinson’s disease; RT-qPCR,
quantitative real-time polymerase chain reaction; SEM, standard error of the mean;
SN DA, substantia nigra dopamine neurons; TH, tyrosine hydroxylase; VMAT2, vesic-
ular monoamine transporter 2.
Table 2
Relative mRNA levels in SN DA neurons from controls and PD brains, without and with mathematical adjustment for RIN and age. Relative mRNA levels (mean  SEM,
determined via RT-qPCR) in individual SN DA neurons from PD brains compared with those from controls (given as pg-equivalents of standard SN cDNA per neuron), without
and after adjustment for age- and RIN-inﬂuence
Experimental
series
Gene n Relative expression (pg cDNA/cell) RIN and age corrected relative expression (pg cDNA/cell)
CTR PD CTR SEM PD SEM p PD/CTR CTR SEM PD SEM p PD/CTR
Random 1a ATP13A2 37 29 63.97 17.29 695.09 77.22 <1 3 10L6 10.87 85.93 21.48 569.26 115.06 <1 3 10L6 6.62
SNCA 39 30 47.15 14.23 303.90 40.70 <1 3 10L6 6.45 58.87 15.43 259.66 58.88 <1 3 10L6 4.41
TH 38 31 1139.08 451.35 11,641.23 1770.65 <1 3 10L6 10.22 1106.28 336.10 11,350.03 2524.68 <1 3 10L6 10.26
UCHL1 39 32 132.80 34.11 765.77 106.04 <1 3 10L6 5.77 169.07 42.15 687.17 147.05 <1 3 10L6 4.06
Random 2 DAT 36 39 39.96 11.45 150.83 22.45 <1 3 10L6 3.77 52.66 14.18 122.89 23.15 4.163 10L5 2.33
TH 42 43 248.04 81.52 1849.62 359.46 <1 3 10L6 7.46 320.62 86.56 1307.27 276.91 <1 3 10L6 4.08
VMAT2 15 33 23.22 3.82 69.00 13.12 2.543 10L4 2.97 53.68 18.05 45.99 10.18 0.66 0.86
Random 3 PARKIN 8 10 875.30 622.13 4685.76 1137.45 1.063 10L3 5.35 NA
SNCA 63 41 192.95 30.59 1465.18 278.79 <1 3 10L6 7.59 247.21 42.95 1098.55 235.20 <1 3 10L6 4.44
SNCA112 16 18 37.31 16.23 87.92 24.92 5.643 10L3 2.36 67.03 40.90 56.78 24.12 0.86 0.85
TH 78 47 865.31 309.52 4514.34 918.54 <1 3 10L6 5.22 765.65 175.70 3003.64 634.08 <1 3 10L6 3.92
Random 4 LRRK2 26 30 5.84 1.64 6.05 0.84 0.14 1.04 6.30 1.88 7.23 1.57 0.29 1.15
NURR1 28 34 36.25 6.74 44.92 10.95 1.00 1.24 69.59 17.40 22.28 5.73 2.353 10L5 0.32
TH 64 48 214.36 43.94 2818.29 734.13 <1 3 10L6 13.15 251.14 49.15 1985.90 455.40 <1 3 10L6 7.91
miScript 5 miR-
133b
15 12 4.53 1.93 6.59 2.16 0.13 1.46 8.98 8.12 12.76 10.99 0.42 1.42
PITX3 5 8 525.59 106.66 666.40 63.93 0.22 1.27 NA
SNCA 27 40 8.06 1.27 63.11 8.34 <1 3 10L6 7.83 22.89 7.80 52.04 11.58 1.023 10L3 2.27
TH 35 44 224.15 51.59 2426.00 324.47 <1 3 10L6 10.82 483.10 147.05 1977.50 415.15 <1 3 10L6 4.09
Differences were tested for signiﬁcance with the Welch test after log-transformation (see Section 2).
Bold p-values indicate signiﬁcant (p < 0.05) differences between CTR and PD.
Key: CTR, control; cDNA, complementary DNA; mRNA, messenger RNA; PD, Parkinson’s disease; RIN, RNA integrity numbers; RT-qPCR, quantitative real-time polymerase
chain reaction; SEM, standard error of the mean; SN DA, substantia nigra dopamine neurons; TH, tyrosine hydroxylase.
a Data for TH, SNCA, and ATP13A2 are adapted from (Grundemann et al., 2008; Ramirez et al., 2006).
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qPCR results, we used it for analysis of mRNA levels in individual,
laser-microdissected SN DA neurons. For UV-LMD of individual
neuromelanine-positive SN DA neurons, horizontal kryosections of
the 8 controls and 5 PD brains (Table 1) were mounted on PEN
membranes. We noted that the tissue integrity of all PD brains was
appearing different to that of the control brains (Fig. 2A and B), PD
tissue-integrity seemed to be better, presumably due to a reactive
gliosis in the PD brain (Ahn et al., 2012; Cz1onkowska and
Kurkowska-Jastrze˛bska, 2011). Only neuromelanine-positive neu-
rons with visible nuclei and intact morphology within the SN were
laser-microdissected (Fig. 2A and B) and lysed for subsequent RT-
qPCR analysis.
We analyzed the expression of several dopamine maintenance
and release genes (SNCA, TH, DAT, VMAT2, NURR1, PITX3) and PARK
genes (SNCA, ATP13A2, UCHL1, PARKIN, LRRK2) as well as the
microRNA miR-133b.
We evaluated miR-133b levels from PD and control midbrain
tissue, as well as from individual SN DA neurons, since a previous
study reported reduced amounts of miR-133b in PD, associated
with increased amounts of DAmaintenance and release genes in PD
brains at the midbrain tissue level (Kim et al., 2007). We conﬁrmed
a reduction of miR-133b in PD at the midbrain tissue level (Fig. 3A
and Supplementary Table S3; note that total % miRNA levels were
also signiﬁcantly lower in PD brain tissue, see Table 1). However, at
the single cell level, we detected no differences in miR-133b levels
in SN DA neurons between PD and controls (Fig. 3B and C,
Supplementary Fig. S2 and Table 2). These results emphasize the
importance of cell-speciﬁcity when comparing gene expression of
complex tissues with variations in the number of target cells
because of disease state, as it is the case for SN DA neurons in
midbrain tissue in PD compared with controls.
In accordance with unaltered miR-133b levels, we detected no
changes in PITX3 and NURR1 levels in PD comparedwith controls at
both, tissue and SN DA speciﬁc level (Fig. 3A and B, Supplementary
Fig. S2, Table 2, and Supplementary Table S3 and S4). PITX3 and
NURR1 expression was suggested to be regulated by miR-133b andis important for speciﬁcation and maintenance of the SN DA
neuronal phenotype (Kim et al., 2007; Volpicelli et al., 2012).
Mathematical adjustment of cell-speciﬁc data for age and RIN ef-
fects of NURR1 expression (3-effects-model) suggests a down-
regulation of NURR1 in PD (Fig. 3C, and Table 2). Moreover, the
model suggests a rather complex change where disease state (PD)
reduced NURR1 expression, while age increased it (Supplementary
Figs. S2 and S3, and Supplementary Table S4). Note that marginal R2
is very low, and the PCV is about 70% (Supplementary Table S2).
This might imply that the model has only little explanatory power
for NURR1, as the variance at the cell level is much larger than inter-
individual variance between brains. Since the model does only ac-
count for inter-individual differences (RIN, age, CTR/PD) but not
expression differences between cells of the same individual, a
prominent variance at the cell level leads to small marginal R2
values. For NURR1most of the inter-individual variance captured by
the model is explained by PD and age (see PCVCTR/PD, PCVþage in
Supplementary Table S2), not by random intercept effects. PITX3
data could not be adjusted for age and RIN, since the algorithm did
not converge to an optimum, due to low number of samples with
positive RT-qPCR results.
In contrast to miR-133b, PITX3, and NURR1, mRNAs for tyrosine
hydroxylase (TH), the rate limiting enzyme for dopamine synthesis,
as well as for SNCA were dramatically increased in SN DA neurons
from PD patients compared with controls (as we had previously
reported Grundemann et al., 2008), reproducible in all experi-
mental series (from consecutive sections of individual brains;
Fig. 2C, Fig. 3AeC, Table 2, and Supplementary Fig. S2). Also,
expression levels of the plasma membrane dopamine transporter
(DAT), important for axonal and somatodendritic dopamine re-
uptake as well as for the vesicular monoamine transporter 2
(VMAT2) were signiﬁcantly increased (Fig. 3B, Table 2, and
Supplementary Fig. S2). Interestingly, increased expression of
VMAT2 in PD is not preserved after adjustment for RIN and age
effects (Fig. 3C and Table 2). This is based on the fact, that VMAT2
expression levels of different brains are well represented by a linear
age dependence (Supplementary Figs. S2 and S3, value of PCVþage in
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Fig. 4. Cell-speciﬁc, positive correlations of elevated mRNA levels for dopamine synthesis and PARK-genes in human SN DA neurons. (AeF) Individual scatter plots of relative mRNA
levels (after model-adjustment) for controls (CTR, white circles) and PD brains (red circles) of selected gene-pairs (logarithmic scales). Ellipses are drawn at the 75% conﬁdence level
for control (black) and PD (red). Elongated ellipses indicate strong correlation. R-values give Pearson correlation coefﬁcients. Signiﬁcant correlations are indicated by asterisks (* p <
0.01, ** p < 0.001, *** p < 0.0001). Differences in correlations of PD and control data were identiﬁed by Steiger Z-test and marked by asterisks. For detailed analysis of all gene-pairs
see Table 3. Abbreviations: mRNA, messenger RNA; PD, Parkinson’s disease; SN DA, substantia nigra dopamine neurons.
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pressions between PD and controls, after adjusting only for
age effects). These ﬁndings further highlight the importance of the
3-effects-model analysis of the RT-qPCR data, as our human PD and
control samples were not perfectly age matched.
As expression levels of the SNCA splice variant SNCA112 have
been associated with higher risk for PD (McCarthy et al., 2011), we
also speciﬁcally analyzed the mRNA levels of SNCA112. Asexpected, SNCA112 was expressed at signiﬁcantly lower levels in
human control SN DA neurons compared with the unspeciﬁc SNCA
assay, which detects SNCA140 as well as SNCA112 (w5%, p <
0.001). A PD-related increased expression of SNCA112 is however
not detected after correction for age and RIN (Fig. 3DeE, Table 2,
and Supplementary Fig. S2). The elevated SNCA112 expression in
the PD cohort is, according to the model analysis, rather associated
with age differences (Supplementary Table S2 and S4; note no
Table 3
Cell-speciﬁc positive correlations of elevated mRNA levels for dopamine synthesis and PARK-genes in human SN DA neurons
Experimental
series
Gene pairs CTR PD All Correlations
comparison
(CTR and PD)
n r p n r p r p p
Random 1a ATP13A2-SNCA 37 0.472 0.003 28 0.636 2.72 3 10L4 0.756 <1 3 10L6 0.36
ATP13A2-TH 36 0.173 0.31 29 0.493 0.007 0.693 <1 3 10L6 0.16
SNCA-TH 38 0.434 0.006 29 0.637 2.00 3 10L4 0.734 <1 3 10L6 0.27
UCHL1-
ATP13A2
37 0.376 0.02 29 0.644 1.63 3 10L4 0.730 <1 3 10L6 0.16
UCHL1-SNCA 39 0.868 <1 3 10L6 30 0.930 <1 3 10L6 0.932 0 0.19
UCHL1-TH 38 0.480 0.002 31 0.661 5.13 3 10L5 0.756 <1 3 10L6 0.28
Random 2 TH-DAT 36 0.581 2.06 3 10L4 39 0.634 1.50 3 10L5 0.705 <1 3 10L6 0.73
VMAT2-DAT 14 0.289 0.32 31 0.301 0.10 0.191 0.21 0.97
VMAT2-TH 15 0.232 0.40 33 0.529 0.002 0.314 0.03 0.30
Random 3 SNCA112-TH 16 0.468 0.07 18 0.144 0.57 0.330 0.06 0.34
SNCA-SNCA112 15 0.247 0.38 18 0.560 0.016 0.326 0.06 0.33
SNCA-TH 63 0.649 <1 3 10L6 41 0.536 3.09 3 10L4 0.721 0 0.40
Random 4 LRRK2-TH 26 0.585 0.002 30 0.152 0.42 0.275 0.04 0.004
NURR1-LRRK2 9 0.400 0.29 21 0.387 0.08 0.185 0.33 0.08
NURR1-TH 28 0.324 0.09 34 0.150 0.40 0.379 0.002 0.07
miScript 5 miR-133b-SNCA 11 0.319 0.34 11 0.214 0.53 0.196 0.38 0.82
miR-133b-TH 15 0.514 0.05 12 0.594 0.042 0.150 0.46 0.005
SNCA-TH 27 0.320 0.10 40 0.622 1.82 3 10L5 0.514 <1 3 10L6 0.13
Cell-speciﬁc correlation and regression analysis of mRNA levels of gene-pairs for SN DA neurons from PD brains compared with controls. Correlation coefﬁcients were
computed on log-transformed data.
SN DA samples (n) were derived from 5 PD brains for all experimental series, and from 5 control brains for random series 1, 2, and miScript series 5, and 8 control brains for
series 3 and 4.
Bold p-values indicate signiﬁcant (p < 0.05) correlations or differences of correlations between PD and control. For details of analysis, see Section 2.
Key: CTR, control; mRNA, messenger RNA; PD, Parkinson’s disease; SN DA, substantia nigra dopamine neurons; TH, tyrosine hydroxylase.
a Data for TH, SNCA, and ATP13A2 analysis adapted from (Grundemann et al., 2008; Ramirez et al., 2006).
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adjusting them for age-effects. Also note that the large PCVCTR/PD is
a consequence of signiﬁcant older ages of PD brains).
As not only SNCA expression is dramatically elevated in SN DA
neurons from PD but also the expression of the p-type ATPase
ATP13A2 (PARK9; Ramirez et al., 2006 as well as Fig. 3DeE, Table 2,
and Supplementary Fig. S2) we determined mRNA levels for 3
further PARK genes: UCHL1, PARKIN, and LRRK2. While for LRRK2
(PARK8) we detected no change in mRNA level in PD samples
compared with controls (Fig. 3DeE, Table 2, and Supplementary
Fig. S2), for UCHL1 (PARK5) and PARKIN (PARK2) we detected
about 5-fold higher mRNA levels in PD (note that only 8 of 78
TH-positive control samples from 3 brains and 10 of 47 TH-positive
PD samples from 4 brains gave RT-qPCR results for PARKIN; this
low brain and sample number prevented the ﬁtting algorithm to
converge to a reliable resulten.a.).
3.4. SNCA mRNA levels correlate with transcripts for dopamine
synthesis in SN DA neurons from PD patients
The increased levels of mRNA for genes involved in dopamine
synthesis and transport as well as for PARK genes suggest an altered
functional state of SN DA neurons from PD patients. To gain further
insights into concerted increased gene expression in surviving SN
DA neurons with conﬁrmed elevated mRNA levels for both TH and
SNCA, we performed a correlation analysis at the level of SN DA
neurons for all analyzed genes within the same experimental series.
A possible signiﬁcant correlation of mRNA expression for 2 genes
was tested after logarithmic transformation by Pearson correlation
coefﬁcient (all correlation data are given in Table 3, while Fig. 4
highlights selected correlations).
We detected a signiﬁcant correlation between TH and DAT
expression, involved in dopamine synthesis and reuptake, thus
determining (in interplay with VMAT2) the free cytosolic dopamine
concentration (Fig. 4A andB and Table 3: controls r¼0.58, p<0.001;PD: r¼ 0.63, p<0.0001). In accordancewith the predominantly age-
related increase in VMAT2 mRNA, identiﬁed by our model analysis,
VMAT2 mRNA level were only weakly correlated to TH, only in PD
(Table 3). Our ﬁnding would be in line with a compensatory genetic
program in PD, leading to a concerted upregulation of dopamine
synthesis, packaging, and release capacity. This interpretation is
further supported by the robust strong positive correlation between
TH-mRNA and SNCA-mRNA detected in 3 independent experiments
(Fig. 4C and Table 3, correlation factors for experimental series
random 1: controls r ¼ 0.43, p ¼ 0.006; PD r ¼ 0.64, p < 0.001;
random 3: controls r ¼ 0.65, p < 0.001; PD r ¼ 0.54, p < 0.001; and
miScript 5: controls r ¼ 0.32, p ¼ 0.1; PD r ¼ 0.62, p < 0.001).
While in our data no correlation between miR-133b levels and
SNCA expression was detectable (Table 3), a negatively correlated
association of miR-133b to TH expressionwas weakly signiﬁcant for
PD samples (Table 3). In light of this ﬁnding, it is tempting to
speculate that in PD miR-133b is involved in a genetic program that
is able to decrease TH expression, and thus dopamine-synthesis,
but note the low sample numbers with positive qPCR for miR-
133b results, which inevitably leads to low power of the statisti-
cal tests.
3.5. SNCA (PARK1/4) expression correlates with transcripts for
ATP13A2 (PARK9) and UCHL1 (PARK5) in SN DA neurons from PD
brains
Given the crucial role of SNCA levels for SN DA degeneration in
PD, and it is still unknown relation to other conﬁrmed PARK genes,
we probed for possible orchestrated increased gene expression of
SNCA and the other PARK genes, for whichwe detected signiﬁcantly
higher mRNA levels in SN DA neurons of PD patients (UCHL1 and
ATP13A2; Fig. 4E and Table 3). We detected the strongest, highly
signiﬁcant, positive pair-wise correlation for SNCA and UCHL1
mRNA levels in SN DA neurons from control as well as from PD
brains (Fig. 4D). We also found a strong positive signiﬁcant
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quently, also for UCHL1 and ATP13A2 in SN DA neurons from con-
trols as well as from PD (Fig. 4E and F). These data indicate strongly
coupled gene expression of SNCA, UCHL1, and ATP13A2, already
present in SN DA neurons under control conditions, showing a
concerted upregulation in PD.
4. Discussion
To address the complex cellular transcriptome inwhich different
RNA species interact in a network (Salmena et al., 2011), we
extended our mRNA quantiﬁcation method for human SN DA
neurons to allow unbiased parallel quantiﬁcation of mRNAs and
miRNAs from the same UV-LMD sample via RT-qPCR. Variable RNA
integrities (RIN) are unavoidable across human postmortem sam-
ples with individual, non-standardized premortal and postmortal
history. RIN variability can signiﬁcantly bias microarray and RT-
qPCR gene expression results (Schwarz, 1978), a possible explana-
tion for differences in results of various expression-proﬁling studies
(Bustin et al., 2010; Grundemann et al., 2008; Vermeulen et al.,
2011). However, both, our newly developed miScript protocol and
our previously described random primer based RT-qPCR protocol
performed equally well for samples with differentially degraded
mouse RNA within the RIN-range of the human brains, analyzed
here (Fig. 1BeE).
To further dissect possible confounding contributions of the
covariables age and RIN to the observed expression changes for the
individual tested genes in SN DA neurons from PD brains, compared
with that of controls, we developed a linear-mixed 3-effects model
(Snijders and Bosker, 2011). Bias in the analysis and interpretation
of expression data because of covariables can be reduced by optimal
matching in the study design and stratiﬁcation (Consonni et al.,
1997). However, stratiﬁcation needs large sample numbers on
each hierarchical level with possible confounders (i.e. brains in our
case). This is usually particularly difﬁcult to achieve for limited
human samples, such as human postmortem brain samples
(McNamee, 2005). The brains provided for this study were not
perfectly matched in regard to their RNA quality (RIN value) and the
age of donors. Since both quantities have to be considered as
relevant confounders, their inﬂuence on detected gene expression
values had to be estimated. We have statistically reanalyzed data
with our linear-mixed 3-effects model, a method based on math-
ematical regression (Consonni et al., 1997; McNamee, 2005). All
model details, the algorithm, and its evaluation are discussed in
detail in the supplement.
With this novel methodological approach, we detected orches-
trated, positively correlated elevated expression of dopamine ho-
meostasis genes (TH, DAT, VMAT2, SNCA) as well as PARK-genes
(SNCA, ATP13A2, UCHL1, PARKIN) in remaining human SN DA
neurons from PD brains compared with those of controls. These
changes were not associated with reduced levels of miR-133b, as
recently suggested (Kim et al., 2007). However, our correlative
expression data do not give direct proof or provide insight into the
mechanisms of gene interaction, and differences in mRNA abun-
dances might not always simply be translated into different abun-
dances of functional proteins (Tang et al., 2011; Tobin, et al., 2009).
For most genes, for which we detected signiﬁcantly higher
mRNA levels in SN DA neurons from PD compared with controls,
the model also predicted predominantly disease-associated in-
creases, not caused by age or RIN (TH, SNCA, DAT, PARKIN, UCHL1,
ATP13A2). For VMAT2 and SNCA112 modeling suggested an age-
dependent change with no or only moderate effects of PD. For
NURR1 the model suggested a PD related reduction of expression in
SN DA neurons, which was compensated by an age-related increase
in mRNA levels. Although it is tempting to speculate that age-dependent changes in gene expression could be causative for PD,
it has to be emphasized that the model results are in general based
on a low number of brains giving more or less large inter-individual
differences in covariables and RT-qPCR results, thus such conclu-
sions certainly need further investigation. However, the model
reliably allows us to exclude relevant bias of our gene expression
data by differences in RNA quality (compare Supplementary
Table S2 and S4), a prerequisite when performing RT-qPCR anal-
ysis for samples with signiﬁcantly different RIN, as it was the case
for our human brain samples.
4.1. Cellular speciﬁcity is critical for detecting concerted changes of
gene expression in SN DA neurons in PD
Cell-speciﬁc gene expression analysis is the desired standard for
quantiﬁcation of individual mRNA or miRNA species, and as shown
here, to identify cell-speciﬁc concerted correlations of gene
expression at the RNA level (Ransdell et al., 2010; Stahlberg et al.,
2011; Tang et al., 2011; Tobin et al., 2009). Cell speciﬁcity is impor-
tant for understanding the transcriptional networks that deﬁne
distinct cellular phenotypes (Schulz et al., 2007; Tobin et al., 2009),
aswell as to identify cell-speciﬁc perturbations in disease. Studies of
genetic interactions and responses to alpha-synuclein over-
expression and its toxicity havebeen carried out inmodel organisms
(Auluck et al., 2010), reporting upregulations of several genes in
response to alpha-synuclein overexpression, however, up to now
only at the tissue level (Scherzer et al., 2003; Vartiainen et al., 2006).
However, in the pars compacta of human SN, most neurons are
dopaminergic and in PD motor symptoms manifest when approx-
imately 70% of these DA neurons are already lost (Damier et al.,
1999). Thus, midbrain tissue in PD and control brains is composed
of a signiﬁcantly different mix of DA and non-DA (e.g., glia, GABA)
cells. In addition to the dramatic reduction of DA neurons in
midbrain tissue in PD, analysis at the tissue level is additionally
confounded by altered numbers and functional states of non-
neuronal cells like microglia, astrocytes, and local T-cells (Hirsch
and Hunot, 2009; Schwarz, 1978). Thus, cell-speciﬁcity is crucial
when comparing gene expression changes in the SN in PD and
control states. As we show here, the problem of detected tissue-
based, artiﬁcial differences in gene expression between PD and
control midbrains also applies to qPCR-based quantiﬁcation of
miRNAs, and might explain recent controversial ﬁndings from
tissue-based studies (de Cremoux et al., 2011; Jung et al., 2010; Kim
et al., 2007; Opitz et al., 2010; Schwarz, 1978).
For miR-133b, DAT, and VMAT2 we obtained different results
between tissue level-based and cell-speciﬁc RNA quantiﬁcation.
Only themost prominent elevation of TH in SN DA neurons from PD
brains compared with controls was still detectable at the midbrain
tissue level. Restricting the analysis to the tissue level would miss
gene expression changes of DAT and VMAT2, as it might have
occurred in various SN tissue-based expression studies (Lesnick
et al., 2007; Mandel et al., 2005; Moran et al., 2006; Zhang et al.,
2005). This indicates that extrapolations of expression results
based onwhole SN midbrain tissue to the individual SN DA neuron,
as recently done for miR-133b (Kim et al., 2007), (Junn and
Mouradian, 2012; for critical discussion), might be misleading
(Fig. 3). Similar as Kim et al. (2007), we detected signiﬁcantly
reduced amounts of miR-133b inwhole SNmidbrain tissue from PD
patients compared with controls. However, at the cell-speciﬁc level
of individual neuromelanine-positive SN DA neurons, miR-133b
expression was not altered in PD compared with control, in accor-
dance with recent similar notes (Heyer et al., 2012; Minones-
Moyano et al., 2011; Sonntag, 2010). Accordingly, variants in
miR-133 and PITX3 genes in PD patients and controls seem not to
contribute to the risk for PD (de Mena et al., 2010).
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PARK genes in SNCA-overexpressing SN DA neurons from PD brains
In individual SN DA neurons, we detected signiﬁcantly higher
mRNA levels of VMAT2 < DAT < SNCA112 < UCHL1 < PARKIN in
our PD brains, in addition to those of TH, SNCA, and ATP13A2 as
previously described (Grundemann et al., 2008; Ramirez et al.,
2006) (Fig. 3 and Table 2).
Our ﬁndings for TH, DAT, SNCA, UCHL1, and ATP13A2 in PD
brains are in contrast to another SN DA-speciﬁc UV-LMD based
RT-qPCR study (Simunovic et al., 2009), most likely because of
methodological differences (different SN DA sampling sizes, pre-
ampliﬁcation, and normalization to housekeeping genes).
PARKIN is involved in catabolic autophagy and mitophagy,
essential for organelle quality control and global starving response
(Youle and Narendra, 2011) that might be particularly important in
PD, as a protective response to an increased load of neurotoxic
alpha-synuclein (Kamp et al., 2010; Moszczynska et al., 2007).
4.3. Positive correlation of mRNA levels for TH-DAT-VMAT2 in
SNCA-overexpressing SN DA neurons in PD
We show that SNCA mRNA abundance is positively correlated
with that of TH (the rate-limiting enzyme for dopamine synthesis)
in SN DA neurons from controls as well as from PD brains. THmRNA
expressionwas further correlated with DAT mRNA, which codes for
the dopamine uptake transporter and only in PD patients positively
correlated with the mRNA of the vesicular monoamine transporter
VMAT2. The increased expression of TH, DAT, and VMAT2 together
with SNCA in SN DA neurons in the PD brains is in accordance with
increased dopamine-release machinery because of SN DA neuron
loss in PD or older age (Li et al., 2010). Our ﬁndings might indicate a
larger transcriptional or mRNA stability network (Reddy et al.,
2011), enabling surviving SN DA neurons in advanced PD to syn-
thesize (TH), package (VMAT2), release (SNCA), and re-uptake
(DAT) dopamine (Zhou et al., 2011). For example, TH, DAT, and
VMAT2 expression are all regulated by BDNF signaling (Boger et al.,
2011; Fukuchi et al., 2010; Ziebell et al., 2010). Increased expression
of SNCA, possibly mediated by altered SNCA-methylation (Jowaed
et al., 2010) or reduced miRNA activity (Jung et al., 2010; Wang
et al., 2008) might be a trigger for SN DA degeneration and PD
but also be embedded in this compensatory response of the
dopamine system (Lundblad et al., 2012). Of 4 isoforms of SNCA
(generated by alternative splicing of exons 3 and 5: Venda et al.,
2010), the SNCA112 splice variant (no exon 5) was found in
particular in brains from patients with Lewy body disease and its
levels were upregulated in cell culture by the PD toxin MPPþ
(Kalivendi et al., 2009; Venda et al., 2010). Therefore, we speciﬁcally
analyzed mRNA levels of SNCA112 in SN DA neurons from PD and
control brains and detected a 2.4-fold increase in SNCA112mRNA in
our PD brains. Although, ourmodel suggested that this increasewas
mainly related to age, therewas a signiﬁcant correlation of SNCA112
mRNA levels with that of the unspeciﬁc SNCA assay (detecting full
length SNCA140 þ 112) only in PD (Table 3). This might support the
idea of PD-associated alternative SNCA splicing as a protective
strategy during global SNCA overexpression (McCarthy et al., 2011;
McLean et al., 2011; Venda et al., 2010).
4.4. Positive correlation of mRNA levels for UCHL1 and ATP13A2 in
SNCA-overexpressing SN DA neurons in PD
In addition to facilitating dopamine release, increased levels of
alpha-synuclein are also expected to increase the toxic protein load
for proteasomal and lysosomal protein degradation (Auluck et al.,
2010). A prominent modiﬁer gene for alpha-synucleinoverexpression-induced toxicity is ATP13A2 (PARK9), a lysosomal
ATPase of still unknown function (Gitler et al., 2009; Radi et al.,
2011). The PD-mutated form of ATP13A2 sensitizes cells to ER-
stress induced cell death (Ugolino et al., 2011). ATP13A2 (PARK9)
has been identiﬁed as a suppressor of alpha-synuclein toxicity
(Gitler et al., 2009). Accordingly, ATP13A2 mRNA levels are
increased in remaining SN DA neurons from sporadic PD patients
compared with controls (Ramirez et al., 2006).
Our study demonstrates that in SNDAneurons of controls aswell
as PD, SNCA, and ATP13A2 expression is positively correlated, indi-
cating that ATP13A2 expression might be scaled-up in PD in
response to a toxically increased alpha-synuclein load. We detected
an even stronger signiﬁcant correlation between SNCA mRNA
expression and UCHL1 (PARK5), and accordingly also between
ATP13A2 and UCHL1 in SNDA neurons from controls and PD. UCHL1
is an ubiquitin hydrolase that is a component of the ubiquitin-
proteasome pathway, and has been identiﬁed together with alpha-
synuclein in Lewy bodies (Yasuda et al., 2009). Increased striatal
UCHL1 expression is also present in a mouse overexpressing wild-
type SNCA (Prasad et al., 2011) and reduced UCHL1 levels reduce
neuronal survival (Lombardino et al., 2005). These ﬁndings indicate
a concerted regulation of these PARK-genes in SN DA neurons in PD,
as a protective response to increased proteasomal and lysosomal
and/or autophagosomal demands. The ﬁnding that LRRK2 (PARK8)
mRNA levels were not altered in remaining DA neurons from PD
brains is in accordancewith a study showing that pathogenic LRRK2
mutations do not alter gene expression in human brain tissue
(Devine et al., 2011a). Increased expression of wild-type LRRK2 ac-
celerates alpha-synuclein-induced neurodegeneration and is thus
notexpected as anallostatic survivalmechanismof SNDAneurons in
PD (Caguci, 2003; Lin et al., 2009).
In summary, we identiﬁed a concerted upregulation of selected
dopamine homeostasis and PARK genes in surviving, alpha-
synuclein and TH overexpressing human SN DA neurons in spo-
radic PD, apparently not orchestrated by altered miR-133b
levels. This correlated increase of mRNAs in SN DA neurons from
sporadic PD patients suggests a coupling of disease-triggering
alpha-synuclein expression in SN DA neurons with transcriptional
compensatory programs. This might favor a functional compensa-
tion network in SN DA neurons to increase their dopamine release
(TH, DAT, VMAT2, and SNCA) and, on the other hand, to stimulate
proteasomal (UCHL1, PARKIN) as well as lysosomal (ATP13A2)
function to counteract alpha-synuclein toxicity. This compensatory
network might be orchestrated at the level of, for example, stress-
induced speciﬁc transcription factors, joinedly regulating these
genes. However, further studies (e.g., promotor-analyses) are
needed to test this hypothesis.
Global gene expression studies addressed gene networks of
transcriptional dysregulation for mammalian DA neurons in PD
(Elstner et al., 2011; Greene, 2011; Moran and Graeber, 2008).
Expression proﬁling studies and complementary genetic screens
resulted in largely nonoverlapping gene lists (Schwarz, 1978),
which are integrated in novel bioinformatics tools such as
ResponseNet (Yeger-Lotem et al., 2009). Future cell-speciﬁc gene
expression data need to extend and combine all these approaches,
ideally with parallel analysis of respective genetic risk factors to
deﬁne whether mRNA level correlations, as well as certain micro-
RNA expression patterns constitute molecular signatures of sur-
viving SN DA neurons in PD patients (Palm et al., 2012), and thus
offer molecularly deﬁned targets for protecting DA neurons.
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